Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency
- 21 May 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (21), 2191-2201
- https://doi.org/10.1056/nejmoa0805840
Abstract
Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity. We conducted a randomized, double-blind, placebo-controlled trial of extended-release dipyridamole, at a dose of 200 mg, and aspirin, at a dose of 25 mg, given twice daily after the placement of a new arteriovenous graft until the primary outcome, loss of primary unassisted patency (i.e., patency without thrombosis or requirement for intervention), was reached. Secondary outcomes were cumulative graft failure and death. Primary and secondary outcomes were analyzed with the use of a Cox proportional-hazards regression with adjustment for prespecified covariates. At 13 centers in the United States, 649 patients were randomly assigned to receive dipyridamole plus aspirin (321 patients) or placebo (328 patients) over a period of 4.5 years, with 6 additional months of follow-up. The incidence of primary unassisted patency at 1 year was 23% (95% confidence interval [CI], 18 to 28) in the placebo group and 28% (95% CI, 23 to 34) in the dipyridamole–aspirin group, an absolute difference of 5 percentage points. Treatment with dipyridamole plus aspirin significantly prolonged the duration of primary unassisted patency (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P=0.03) and inhibited stenosis. The incidences of cumulative graft failure, death, the composite of graft failure or death, and serious adverse events (including bleeding) did not differ significantly between study groups. Treatment with dipyridamole plus aspirin had a significant but modest effect in reducing the risk of stenosis and improving the duration of primary unassisted patency of newly created grafts. (ClinicalTrials.gov number, NCT00067119.)This publication has 33 references indexed in Scilit:
- Current Management of Vascular AccessClinical Journal of the American Society of Nephrology, 2007
- Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trialThe Lancet, 2006
- Hemodialysis Vascular Access DysfunctionJournal of the American Society of Nephrology, 2006
- Design of the Dialysis Access Consortium (DAC) Aggrenox prevention of access stenosis trialClinical Trials, 2005
- Natural history of arteriovenous grafts in hemodialysis patientsAmerican Journal of Kidney Diseases, 2000
- Clinical Measurement of Blood Flow in Hemodialysis Access Fistulae and Grafts by Ultrasound DilutionASAIO Journal, 1995
- Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplastyJournal of the American College of Cardiology, 1994
- DRUG-INDUCED INHIBITION OF PLATELET FUNCTION DELAYS PROGRESSION OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE: A Prospective Double-Blind Arteriographically Controlled TrialThe Lancet, 1985
- Effect of antiplatelet therapy on restenosis after experimental angioplastyThe American Journal of Cardiology, 1984
- Effect of Dipyridamole and Aspirin on Late Vein-Graft Patency after Coronary Bypass OperationsNew England Journal of Medicine, 1984